

# CITATION REPORT

List of articles citing

**Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects**

**DOI: 10.1080/13543784.2021.1863371**

**Expert Opinion on Investigational Drugs, 2021, 30, 185-192.**

**Source:** <https://exaly.com/paper-pdf/77924426/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta <sup>®</sup> in Healthy Chinese Male Volunteers. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 660541	5.6	0
6	A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta <sup>®</sup> in healthy Chinese male subjects. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-9	5.4	0
5	Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 821944	5.6	0
4	The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva <sup>®</sup> ) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.. <i>International Immunopharmacology</i> , <b>2022</b> , 107, 108666	5.8	2
3	A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
2	Editorial: Women in drug metabolism and transport: 2021. 13,		
1	Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study. <b>2023</b> , 38, 117-125		0